GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Gsk3b | affects response to substance | ISO | GSK3B (Homo sapiens) | 6480464 | CTD | GSK3B protein affects the susceptibility to troglitazone | PMID:20540935 | Gsk3b | decreases activity | ISO | GSK3B (Homo sapiens) | 6480464 | CTD | troglitazone results in decreased activity of GSK3B protein | PMID:20540935 | Gsk3b | multiple interactions | ISO | GSK3B (Homo sapiens) | 6480464 | CTD | [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CCNB1 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CCND1 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CCNE1 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CDK2 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in decreased expression of CDK4 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in increased expression of BAX protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in increased expression of CASP3 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] results in increased susceptibility to [Troglitazone results in increased expression of CASP9 protein]; [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] which results in increased susceptibility to Troglitazone; GSK3B protein affects the susceptibility to [Troglitazone results in decreased expression of CCNB1 protein]; GSK3B protein affects the susceptibility to [Troglitazone results in decreased expression of CCND1 protein]; GSK3B protein affects the susceptibility to [Troglitazone results in decreased expression of CCNE1 protein]; GSK3B protein affects the susceptibility to [Troglitazone results in decreased expression of CDK2 protein]; GSK3B protein affects the susceptibility to [Troglitazone results in decreased expression of CDK4 protein]; GSK3B protein affects the susceptibility to [Troglitazone results in increased expression of BAX protein]; GSK3B protein affects the susceptibility to [Troglitazone results in increased expression of CASP3 protein]; GSK3B protein affects the susceptibility to [Troglitazone results in increased expression of CASP9 protein] | PMID:20540935 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |